Been digging into the gene editing space lately and honestly, there's something interesting happening here that most people overlook. While everyone's chasing growth stories with zero profits, there are actually some top gene editing stocks that are already making real money or have a clear path to it.

Let me break down what caught my attention. Gene editing technology has matured enough that we're seeing actual commercial success now, not just lab promises. The most relevant approach is CRISPR-Cas9, which remains the most accurate, fastest, and most cost-effective method out there.

First up is CRISPR Therapeutics. They literally created the dominant gene editing tech everyone's using. Their Casgevy drug just got FDA approval and it's honestly a game-changer for sickle cell disease and transfusion-dependent beta-thalassemia. Think about it - over 100,000 Americans deal with sickle cell disease. That's a massive addressable market. The drug is priced at around $2.2 million per dose, which tells you something about the value proposition here. Sure, they're burning cash on R&D and market expansion right now, but they've got over $2 billion sitting in reserves. That's serious runway. This is why top gene editing stocks like CRSP get so much analyst attention.

Then there's Vertex Pharmaceuticals. Here's what makes them different - they're already profitable. Like, actually making money for the past five years. They partnered with CRISPR Therapeutics on Casgevy and got their own FDA approvals for the same indication. Analysts are rating it as a buy. Casgevy is expected to hit around $400 million in peak annual sales for Vertex alone. That's real revenue, not theoretical.

The third one that's been on my radar is Schrödinger. This is more of a software play in the gene editing ecosystem. They built a computational platform for drug discovery and they're selling access to pharma firms working on gene editing. They're leveraging AI to accelerate molecular discovery, which is clever positioning. The consensus is pretty bullish - analysts are forecasting the stock could more than double. It's interesting because Schrödinger touches the entire pharma sector but has particular relevance for top gene editing stocks and their research needs.

What I find compelling is that these aren't just hype plays. You've got companies with either current profitability or near-term visibility to it, combined with exposure to one of the most promising biotech trends. The gene editing market is real now, not speculative. If you're looking at this sector, these are the names worth watching because they're actually executing, not just promising.